← Research library

The effect of bemetil on production of DNA antibodies in patients with systemic lupus erythematosus

Comparison in people · 1999

What was studied
61 people with SLE; four groups of 15, 15, 15 and 16; eight-week comparison
Main finding
A four-group lupus report associated Bemitil-containing treatment with lower anti-DNA antibody levels and disease-activity scores; the abstract does not give numerical changes.

Antibodies and lupus activity · Reported decreases in anti-DNA antibodies, SLEDAI-1 and ECLAM scores · No group-level values or effect sizes in abstract

Reported findings and study design

A four-group lupus report associated Bemitil-containing treatment with lower anti-DNA antibody levels and disease-activity scores; the abstract does not give numerical changes.

Four groups of 15, 15, 15 and 16 patients; background prednisolone with different adjuncts; eight-week assessment.

Dose, route and schedule

Bemitil: 500–750 mg/day orally for eight weeks, studied alone or with cyclophosphamide. Combination-arm results do not establish Bemitil’s independent effect.

Protocol source ↗ · Indexed publication abstract

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Antibodies and lupus activityReported decreases in anti-DNA antibodies, SLEDAI-1 and ECLAM scoresNo group-level values or effect sizes in abstract
Group sizes15, 15, 15 and 16 patientsThe count spans multiple groups.
Bemitil exposure500–750 mg/day orallyEight-week comparison; the indexed background-drug dose units need original verification

Several concurrent-treatment arms prevent interpreting this as Bemitil monotherapy. Unverified background-drug units are not reproduced as dosing instructions.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • SLE is a different disease; these findings do not establish efficacy in MS.
  • Allocation and blinding cannot be established from the abstract; concomitant therapy complicates attribution.
  • The 1997 dissertation and 2000 patent appear to describe the same research program.

Related publications may describe some of the same participants or experiments.

Source details

Indexed English abstract

The summary reflects the results reported in the cited source.

Abstract reviewed

Sources checked

Citation

Human comparative studyEnglish abstract

T. A. Lisitsyna, A. D. Durnev, M. M. Ivanova, A. I. Speranskii, S. B. Seredenin, V. A. Nasonova. The effect of bemetil on production of DNA antibodies in patients with systemic lupus erythematosus Experimental and Clinical Pharmacology. 1999;62(5):38–41. PMID 10572751

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards